...or not. But hey, "ICNB: We are awaiting final approval

New Post Public Reply Private Reply Replies (0) Message Board
joey68 joey68 #258
330
...or not. But hey, "ICNB: We are awaiting final approval from our California distributor and hope to be in stores by months end". Within a week or so we should be hearing more about Bevmo.

Nice green close for ICNB
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honoring Dr. Drew's Impact on Blood Banking History

Updated Category News Views 1

Legacy of Dr. Charles R. Drew Comes Alive Here's one for the books: a legacy that's still saving lives 85 years after it began. Dr. Charles R. Drew, the mastermind behind blood banking, is getting his due respect with a documentary called Iconic Excellence. No fluff here—this film unveils how the man's breakthroughs during World War II laid down the bedrock of modern...

Continue Reading
Catholic Colleges Excel in AI Readiness, Study Shows

Updated Category News Views 3

Faith and Tech: An Unexpected Alliance? Alright, here's something that'll make you sit up: Catholic college grads are not just busy sipping their morning coffee while they muse over moral philosophy—they're out there on the front lines of artificial intelligence, better prepared and more engaged than their peers from secular schools. According to the latest Holistic...

Continue Reading
Capricor Faces Lawsuit: Investors Should Take Note

Updated Category News Views 4

Capricor Therapeutics: A Rough Road Ahead If you've got skin in the game with Capricor Therapeutics, these latest developments might have you feeling a bit queasy. Forget the greasy diner fare today; this situation calls for some serious contemplation and maybe a bit of antacid. Over at NASDAQ:CAPR, the air is hot with allegations, stock price nosedives, and looming legal...

Continue Reading
Hisense and UEFA 2028: A Winning Partnership Experience

Updated Category News Views 0

Hisense Extends its UEFA Adventure You ever get the feeling that some partnerships are like a football match made in heaven? Well, Hisense surely seems to think so as they've renewed their gig with UEFA for the 2028 European Championship. That's their fourth tango with UEFA, a relationship that's matured like a fine wine since it all kicked off in 2016. Now, if you're...

Continue Reading
Médunik Canada Boosts Dravet Syndrome Support with Biocodex

Updated Category News Views 1

Breaking Down the Exclusive Médunik-Biocodex Partnership Listen, when a company like Médunik Canada, firmly rooted in Blainville, QC, throws its weight behind a rare disease drug like Diacomit®, folks in the industry take notice. Their recent handshake with Biocodex isn't just small talk; it opens doors to change how Dravet syndrome is managed across Canada. This new...

Continue Reading
United Imaging's CE Mark Ignites CT Innovation in Europe

Updated Category News Views 5

United Imaging's Big Leap in CT Technology Listen up, folks. United Imaging just got the go-ahead to shake things up in Europe with their dual wide-coverage CT family. We're talking about the uCT SiriuX and the even more amped-up uCT SiriuX Ultrix. They’ve snagged the CE mark, a passport to roll out these impressive machines across the continent. Revolutionizing...

Continue Reading
Key Considerations for a Landscape Redesign

Updated Category News Views 2

Starting Your Landscape Redesign the Right Way I’ll give it to you straight: redesigning your yard isn’t just about tossing in some new plants and hoping for the best. Anyone aiming for some backyard nirvana needs to think about the gritty details first—things like drainage, compatibility, and the future growth of those leafy inhabitants. Taking it from Tim Wasmer...

Continue Reading
BRP's C-Suite Shakeup: What It Means for Investors

Updated Category News Views 2

Passing the Baton in BRP's Financial Helm Alright, folks, grab your coffee and listen up. There's a shakeup coming from the cold corners of Valcourt, Quebec—BRP Inc., the powersports behemoth on the TSX: DOO, has announced a changing of the guard in their finance department. Come October 1st, there's a planned power shift as Sébastien Martel steps down as CFO, passing...

Continue Reading
Aardvark Therapeutics Faces Investor Lawsuit for Fraud

Updated Category News Views 1

Investors' Trust on Shaky Grounds There it is, staring right back at investors: a securities fraud class action lawsuit against Aardvark Therapeutics. Not exactly the news a shareholder wants to digest over breakfast. If you’ve got skin in the game with Aardvark Therapeutics (NASDAQ: AARD), you might wanna keep reading. Hagens Berman Sobol Shapiro LLP, a name that's no...

Continue Reading
Jim Morey Joins Pickleman's to Drive Expansion

Updated Category News Views 2

Jim Morey: Catalyst for Pickleman's Ambitious Dreams You ever heard of a sandwich joint ready to take on the big leagues? Because that's just what Pickleman's Gourmet Café is banking on with their latest move—tapping none other than Jim Morey for their executive advisory board. And let me tell ya, this ain't some run-of-the-mill hire. We're talking about a guy who's...

Continue Reading

Top 5 Most Recently Viewed Articles

AirBoss of America Corp. Prepares for Quarterly Earnings Call

Updated Category News Views 114

AirBoss of America Corp. Announces Earnings Release Date AirBoss of America Corp. (TSX: BOS) (OTCQX: ABSSF) has just shared exciting news regarding its upcoming third-quarter results. The company plans to make their earnings announcement after the markets close on Wednesday. This release will be closely followed by a conference call scheduled for the following day, where...

Continue Reading
Sanofi's Strategic Acquisition of Vicebio: A New Era for Respiratory Vaccines

Updated Category News Views 272

Sanofi's Strategic Acquisition of Vicebio In a significant move to strengthen its respiratory vaccines portfolio, Sanofi has made an exciting announcement regarding its acquisition of Vicebio Ltd, a biotechnology company specializing in next-generation vaccines. This acquisition marks a pivotal moment in Sanofi's ongoing commitment to innovation in vaccine development....

Continue Reading
Exploring Moodys Corporation's Short Interest Trends and Insights

Updated Category News Views 239

Moodys Corporation's Short Interest Analysis Moodys Corporation (NYSE: MCO) has experienced a notable decrease in short interest, with the short percent of float dropping by 14.17% since the last report. The recent figures indicate that there are approximately 1.61 million shares sold short, which accounts for about 1.03% of all available shares for trading. Based on the...

Continue Reading
Nautilus Biotechnology Reveals Impressive Q2 2025 Results

Updated Category News Views 262

Nautilus Biotechnology's Q2 2025 Financial Highlights Nautilus Biotechnology, Inc. (NASDAQ: NAUT) has reported its financial results for the latest quarter, showcasing promising advancements in single-molecule proteome analysis. The company continues to innovate as it heads into the upcoming quarters and seeks to solidify its standing in the life sciences sector. Key...

Continue Reading
Understanding Alliance Witan PLC's Recent NAV Performance

Updated Category News Views 139

Insights on Alliance Witan PLC's Net Asset Value Alliance Witan PLC has shared its recent assessment of net asset value (NAV), a crucial indicator for investors looking to gauge the company’s financial health. The latest figures, derived from the bid price basis, provide investors with a clear picture of the company's market standing. Current NAV Per Ordinary Share As...

Continue Reading